or Try an Advanced Search...

    Technical Analysis for ESPR - Esperion Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 1.90 -4.52% -0.09
    ESPR closed down 4.52 percent on Friday, April 26, 2024, on 64 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 7
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical ESPR trend table...
    Date Alert Name Type % Chg
    Stochastic Reached Oversold Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion -4.52%
    Oversold Stochastic Weakness -4.52%
    NR7 Range Contraction -10.80%
    Narrow Range Bar Range Contraction -10.80%
    Wide Bands Range Expansion -10.80%
    Oversold Stochastic Weakness -10.80%
    Wide Bands Range Expansion -9.09%
    Older End-of-Day Signals for ESPR ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 13 hours ago
    Down 3% about 17 hours ago
    60 Minute Opening Range Breakdown about 17 hours ago
    10 DMA Support about 18 hours ago
    Fell Below Previous Day's Low about 18 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ESPR Chart by TradingView
    Basic chart:

    Profile

    Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Diabetes Obesity Lipid Cardiology Cholesterol Lipoprotein Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Atherosclerosis Niacin

    Is ESPR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 25 These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
    Apr 23 Esperion to Report First Quarter 2024 Financial Results on May 7
    Apr 21 11 Best Low Price Pharma Stocks To Invest In
    Apr 8 Esperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groups
    Apr 7 Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
    Apr 1 Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
    Mar 28 Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
    Mar 26 Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
    Mar 25 Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
    Mar 25 Esperion stock jumps 18% in wake of FDA label expansions
    See more ESPR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.4
    52 Week Low 0.7
    Average Volume 6,563,466
    200-Day Moving Average 1.79
    50-Day Moving Average 2.40
    20-Day Moving Average 2.37
    10-Day Moving Average 1.95
    Average True Range 0.24
    RSI (14) 38.27
    ADX 24.4
    +DI 16.89
    -DI 25.69
    Chandelier Exit (Long, 3 ATRs) 2.68
    Chandelier Exit (Short, 3 ATRs) 2.43
    Upper Bollinger Bands 3.35
    Lower Bollinger Band 1.39
    Percent B (%b) 0.26
    BandWidth 82.72
    MACD Line -0.15
    MACD Signal Line -0.11
    MACD Histogram -0.04
    Fundamentals Value
    Market Cap 339.95 Million
    Num Shares 179 Million
    EPS -2.27
    Price-to-Earnings (P/E) Ratio -0.84
    Price-to-Sales 4.49
    Price-to-Book 74.89
    PEG Ratio -4.78
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.10
    Resistance 3 (R3) 2.11 2.06 2.06
    Resistance 2 (R2) 2.06 2.01 2.05 2.05
    Resistance 1 (R1) 1.98 1.98 1.96 1.97 2.04
    Pivot Point 1.93 1.93 1.92 1.92 1.93
    Support 1 (S1) 1.85 1.88 1.83 1.84 1.76
    Support 2 (S2) 1.80 1.85 1.79 1.75
    Support 3 (S3) 1.72 1.80 1.74
    Support 4 (S4) 1.71